Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial